U.S. markets open in 8 hours 49 minutes
  • S&P Futures

    3,837.50
    +28.25 (+0.74%)
     
  • Dow Futures

    31,105.00
    +193.00 (+0.62%)
     
  • Nasdaq Futures

    13,058.50
    +147.50 (+1.14%)
     
  • Russell 2000 Futures

    2,231.60
    +32.40 (+1.47%)
     
  • Crude Oil

    62.55
    +1.05 (+1.71%)
     
  • Gold

    1,749.80
    +21.00 (+1.21%)
     
  • Silver

    27.05
    +0.61 (+2.31%)
     
  • EUR/USD

    1.2086
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.4600
    -1.5180 (-100.00%)
     
  • Vix

    27.95
    -28.89 (-100.00%)
     
  • GBP/USD

    1.3982
    +0.0060 (+0.43%)
     
  • USD/JPY

    106.5570
    +0.0550 (+0.05%)
     
  • BTC-USD

    46,278.10
    +1,225.59 (+2.72%)
     
  • CMC Crypto 200

    925.70
    -7.44 (-0.80%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,581.79
    +615.78 (+2.13%)
     

Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2020 Results Presentation and Webcast

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

OSLO, Norway, Feb. 15, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) announces that it will report its results for the fourth quarter and full year 2020 on Thursday, 18 February 2021.

A presentation by Nordic Nanovector's senior management team will be webcast live the same day at 8:30am CET.

The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2020 from 7:00am CET the same day.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535
Email: nordicnanovector@citigatedewerogerson.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-fourth-quarter-and-full-year-2020-results-presentation-and-webc,c3287387

Cision
Cision

View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-invitation-to-fourth-quarter-and-full-year-2020-results-presentation-and-webcast-301228343.html

SOURCE Nordic Nanovector